PRRT (Peptide Receptor Radionuclide Therapy) has been available for many years outside the US. In January of 2018, the FDA approved a PRRT agent, Lutathera. Since then, the treatment has become available at many nuclear medicine centers. PRRT is now an additional tool for the treatment of somatostatin positive receptor NETs. For more information click here.